Biomerieux

Biomerieux EBIT per Employee

The EBIT per Employee of Biomerieux (BIM.PA) as of Nov 21, 2026 is 47,579.48 EUR. In the previous year, EBIT per Employee was 49,919.46 EUR — a change of -4.69% (lower).

EBIT per Employee

47,579.48EUR

YoY

-4.69%

Last updated:

EBIT per Employee of Biomerieux is 2025 47,579.48 EUR. EBIT per Employee of Biomerieux was 2024 49,919.46 EUR. It decreases by -4.69% lower compared to the previous year.

The Biomerieux EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
30,818.14 EUR
Jan 1, 2019
28,054.26 EUR
Jan 1, 2020
46,731.67 EUR
Jan 1, 2021
65,112.34 EUR
Jan 1, 2022
47,460.79 EUR
Jan 1, 2023
37,227.64 EUR
Jan 1, 2024
49,919.46 EUR
Jan 1, 2025
47,579.48 EUR
The Biomerieux EBIT per Employee history
YEAREBIT per EmployeeYoY
47,579.48EUR-4.69%
49,919.46EUR+34.09%
37,227.64EUR-21.56%
47,460.79EUR-27.11%
65,112.34EUR+39.33%
46,731.67EUR+66.58%
28,054.26EUR-8.97%
30,818.14EUR+8.60%
28,376.43EUR+12.39%
25,247.99EUR+14.54%
22,043.24EUR+14.64%
19,228.49EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerieux Stock analysis

What does Biomerieux do? Biomerieux SA is a French company that operates in the field of in vitro diagnostics. The company was founded in 1963 by French biologist Alain Merieux and has since continued to grow. Today, Biomerieux employs around 12,000 people in over 150 countries worldwide and is listed on the Paris Stock Exchange. Biomerieux's business model is based on the development, production, and marketing of diagnostic products for various areas of medicine. This includes infectious diseases, cancer, and cardiovascular diseases. The company is divided into two main business segments: Clinical Diagnostics and Industrial Microbiology. Under the Clinical Diagnostics segment, Biomerieux offers a wide range of diagnostic products for infectious diseases, including molecular diagnostics, blood-based tests, and laboratory automation solutions. Some of the most well-known products include the VIDAS immunodiagnostic test, the FilmArray multiplex PCR test, and the VITEK automated system for microorganism identification. Under the Industrial Microbiology segment, Biomerieux is a leading provider of products for the microbiological analysis of food, beverages, and pharmaceutical products. The company offers a wide range of products for microbiological quality control, which help ensure the safety and quality of food and pharmaceutical products. These include the TEMPO system for assessing microorganism growth and the Bactalert blood culture system for rapid detection of bacteria in blood cultures. In addition to its main business segments, Biomerieux also offers specialty products for use in veterinary diagnostics and water analysis. The company works closely with clinical laboratories and health authorities to improve the diagnosis of infectious diseases and combat epidemics. Over the years, Biomerieux has built a strong research and development department focused on developing innovative diagnostic products. The company has also made a number of strategic acquisitions to expand its product portfolio and enter new markets. For example, in 2020, Biomerieux acquired Suzhou Hybiome Biomedical Engineering in China to strengthen its presence in the Chinese market. In summary, Biomerieux is a leading company in the field of in vitro diagnostics. Its wide range of products and global network make it an important partner for laboratories, hospitals, and the food and pharmaceutical industries. With its strong research and development department and strategic acquisitions, Biomerieux will continue to play a crucial role in the fight against infectious diseases and the improvement of patient care. Biomerieux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerieux stock

EBIT per Employee of Biomerieux is 47,579.48 EUR in 2025.

EBIT per Employee of Biomerieux changed from 49,919.46 EUR to 47,579.48 EUR, representing a -4.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Biomerieux since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Biomerieux historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biomerieux

All Key Metrics — Biomerieux